Study guide

2.2 Heart Failure & Cardiac Arrhythmias

Combined Medical Services Examination UPSC CMS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Logistics & Pattern

1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths

2 Chapter 2: General Medicine - Cardiology & Respiratory

2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism

3 Chapter 3: General Medicine - Gastroenterology & Hepatology

3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes

4 Chapter 4: General Medicine - Nephrology & Endocrinology

4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction

5 Chapter 5: General Medicine - Neurology, Haematology & Infection

5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue

6 Chapter 6: General Medicine - Emergency Medicine & Toxicology

6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology

7 Chapter 7: Paediatrics - Neonatology & Child Growth

7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones

8 Chapter 8: Paediatrics - Child Health & Nutrition

8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning

9 Chapter 9: Surgery - General Surgery, Wounds & Shock

9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery

10 Chapter 10: Surgery - Surgical Specialties I

10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi

11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia

11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease

12 Chapter 12: Obstetrics - Antenatal Care & Complications

12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management

13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH

13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care

14 Chapter 14: Gynaecology & Family Planning

14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods

15 Chapter 15: PSM - Epidemiology & Biostatistics

15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing

16 Chapter 16: PSM - Disease Epidemiology & Programmes

16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling

17 Chapter 17: PSM - Health Planning & Environmental Health

17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education

2.2 Heart Failure & Cardiac Arrhythmias

Key Takeaways Explain This Topic AI

Heart failure is categorized by ejection fraction into HFrEF (LVEF ≤40%), HFmrEF (LVEF 41-49%), and HFpEF (LVEF ≥50%), with B-type Natriuretic Peptide (BNP >100 pg/mL or NT-proBNP >300 pg/mL) serving as the primary diagnostic biomarker.

Guideline-Directed Medical Therapy (GDMT) for HFrEF mandates four foundational pillars proven to improve survival: ARNI (Sacubitril/Valsartan) or ACEi/ARB, Beta-blockers (Carvedilol, Bisoprolol, Metoprolol Succinate), Mineralocorticoid Receptor Antagonists (Spironolactone/Eplerenone), and SGLT2 inhibitors (Dapagliflozin/Empagliflozin).

Atrial Fibrillation stroke risk is quantified using the CHA2DS2-VASc score (score ≥2 in men or ≥3 in women indicates oral anticoagulation with DOACs), while rate control (target resting HR <110 bpm) is achieved using Beta-blockers or Non-dihydropyridine CCBs.

Acute narrow-complex SVT in hemodynamically stable patients is managed sequentially with vagal maneuvers followed by rapid IV push Adenosine (6 mg then 12 mg), whereas ANY hemodynamically unstable tachyarrhythmia demands immediate Synchronized Direct Current Cardioversion.

Last updated: July 2026

  • Heart Failure & Cardiac Arrhythmias
  • 1. Heart Failure Definitions & Classification

Heart Failure (HF) is a complex clinical syndrome resulting from structural or functional impairment of ventricular filling or ejection. It is characterized by elevated intracardiac pressures and inadequate cardiac output at rest or during exercise.

Ejection Fraction Categories (ESC / ACC / AHA Guidelines)

Heart Failure with Reduced Ejection Fraction (HFrEF): L V E F ≤ 40 % LVEF \le 40\% L V EF ≤ 40% . Characterized by impaired myocardial contractility (systolic dysfunction), most commonly secondary to CAD, MI, or dilated cardiomyopathy.

Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF): L V E F 41–49% LVEF \text{ 41–49\%} L V EF 41–49% . Represents a middle spectrum requiring mild systolic dysfunction management.

Heart Failure with Preserved Ejection Fraction (HFpEF): L V E F ≥ 50 % LVEF \ge 50\% L V EF ≥ 50% . Driven by impaired ventricular relaxation and compliance (diastolic dysfunction), strongly linked to long-standing hypertension, aging, obesity, and diabetes mellitus.

Functional & Staging Systems

NYHA Functional Class Symptomatic Limitation ACC/AHA Stage Structural Heart Disease Status

Class I No limitation of physical activity. Ordinary activity does not cause fatigue or dyspnea. Stage A High risk for HF (HTN, CAD, DM) without structural heart disease or symptoms.

Class II Slight limitation of physical activity. Comfortable at rest; ordinary activity results in fatigue/palpitations. Stage B Structural heart disease present (e.g., prior MI, LV hypertrophy) without HF symptoms.

Class III Marked limitation of physical activity. Comfortable at rest; less than ordinary activity causes symptoms. Stage C Structural heart disease with prior or current clinical symptoms of HF.

Class IV Inability to carry on any physical activity without discomfort. Symptoms present even at rest. Stage D Refractory end-stage HF requiring specialized interventions (LVAD, transplant).

2. Diagnostic Workup & Biomarkers

Natriuretic Peptides (BNP & NT-proBNP): Ventricular myocytes release B-type natriuretic peptide in response to wall stress and volume overload.

BNP: < 100 pg/mL <100 \text{ pg/mL} < 100 pg/mL rule-out value in acute dyspnea; > 400 pg/mL >400 \text{ pg/mL} > 400 pg/mL strongly indicates acute HF.

NT-proBNP: < 300 pg/mL <300 \text{ pg/mL} < 300 pg/mL rule-out value; age-adjusted cutoffs for rule-in: > 450 (<50 yrs) >450 \text{ (<50 yrs)} > 450 (<50 yrs) , > 900 (50-75 yrs) >900 \text{ (50-75 yrs)} > 900 (50-75 yrs) , > 1800 (>75 yrs) >1800 \text{ (>75 yrs)} > 1800 (>75 yrs) .

Note: Patients taking Sacubitril/Valsartan (ARNI) will have artificially elevated BNP levels (because Sacubitril inhibits neprilysin which degrades BNP), but NT-proBNP is not degraded by neprilysin and remains accurate.

Transthoracic Echocardiogram (TTE): Essential initial test to measure LVEF, assess valvular structure, wall motion abnormalities, and estimate pulmonary artery systolic pressure (PASP).

Chest X-Ray (ABCDE Criteria):

  • A lveolar edema (bat-wing appearance)
  • B erley (Kerley) B lines (interlobular septal fluid)
  • C ardiomegaly (Cardiothoracic ratio >0.50)
  • D ilated upper lobe vessels (cephalization)
  • E ffusions (pleural, blunting of costophrenic angles)
  • 3. Guideline-Directed Medical Therapy (GDMT) for HFrEF

All patients with HFrEF ( L V E F ≤ 40 % LVEF \le 40\% L V EF ≤ 40% ) must be established on the Four Foundational Pillars of GDMT unless contraindications exist, as each class independently reduces all-cause mortality:

Drug Class Key Mechanisms & Representatives Clinical Pearls & Monitoring

1. ARNI / ACEi / ARB ARNI: Sacubitril/Valsartan (Neprilysin inhibitor + ARB). ACEi: Enalapril, Ramipril, Lisinopril. ARB: Valsartan, Candesartan. ARNI is preferred over ACEi/ARB. Must allow a 36-hour washout period when switching from an ACEi to ARNI to prevent severe angioedema. Monitor Serum K + K^+ K + and Creatinine.

2. Beta-Blockers Carvedilol, Bisoprolol, Metoprolol Succinate (sustained-release). Reduces SNS toxicity and cardiac remodeling. Do not initiate during acute decompensation ; start at low doses when patient is euvolemic.

3. MRAs Spironolactone, Eplerenone (Mineralocorticoid Receptor Antagonists). Blocks aldosterone remodeling. Indicated if L V E F ≤ 40 % LVEF \le 40\% L V EF ≤ 40% . Avoid if Serum K + > 5.0 mEq/L K^+ > 5.0 \text{ mEq/L} K + > 5.0 mEq/L or Serum Creatinine > 2.5 mg/dL >2.5 \text{ mg/dL} > 2.5 mg/dL .

4. SGLT2 Inhibitors Dapagliflozin, Empagliflozin (Sodium-Glucose Cotransporter 2 inhibitors). Reduces HF hospitalizations and cardiovascular mortality regardless of diabetes status. Risk of euglycemic DKA and UTIs.

Additional Therapies & Device Indications

Loop Diuretics (Furosemide, Torsemide): Symptom relief of congestion; does NOT confer mortality benefit , adjust to maintain euvolemia.

Ivabradine: Inhibits funny ( I f I_f I f ​ ) channels in SA node. Indicated if patient is in sinus rhythm with resting heart rate ≥ 70 bpm \ge 70 \text{ bpm} ≥ 70 bpm despite maximal tolerated beta-blocker dose.

Hydralazine + Isosorbide Dinitrate: Indicated in self-identified Black patients with persistent NYHA Class III-IV HFrEF despite GDMT, or in patients intolerant to ACEi/ARB/ARNI due to severe renal impairment or hyperkalemia.

Implantable Cardioverter-Defibrillator (ICD): Primary prevention of sudden cardiac death if L V E F ≤ 35 % LVEF \le 35\% L V EF ≤ 35% despite ≥ 3 \ge 3 ≥ 3 months of optimal GDMT and NYHA Class II-III.

Cardiac Resynchronization Therapy (CRT-D): Indicated if L V E F ≤ 35 % LVEF \le 35\% L V EF ≤ 35% , Sinus Rhythm, and Left Bundle Branch Block (LBBB) with Q R S ≥ 150 ms QRS \ge 150 \text{ ms} QRS ≥ 150 ms .

4. Acute Decompensated Heart Failure (ADHF)

Clinical presentation is categorized based on Hemodynamic Profiles (Forrester Classification):

Warm & Wet (Most Common ~80%): Adequate perfusion, severe congestion. Treated with IV Loop Diuretics (Furosemide IV dose ≥ 1 − 2.5 × \ge 1-2.5\times ≥ 1 − 2.5 × oral home dose) + IV Vasodilators (Nitroglycerin / Nitroprusside if S B P > 110 mmHg SBP > 110 \text{ mmHg} SBP > 110 mmHg ).

Cold & Wet (Cardiogenic Shock with Congestion): Poor perfusion ( S B P < 90 mmHg SBP <90 \text{ mmHg} SBP < 90 mmHg , cold extremities, oliguria, altered sensorium) + congestion. Treated with IV Inotropes ( Dobutamine , Milrinone ) ± \pm ± Vasopressors ( Norepinephrine ) to restore organ perfusion before cautious diuresis.

  • 5. Cardiac Arrhythmias
  • Atrial Fibrillation (AF)

ECG Characteristics: Irregularly irregular ventricular response, absence of distinct P waves, fibrillatory waves (rate 350-600 bpm).

Stroke Risk Stratification (CHA2DS2-VASc Score):

  • C ongestive heart failure (+1)
  • H ypertension (+1)
  • A2 ge ≥ 75 \ge 75 ≥ 75 years (+2)
  • D iabetes mellitus (+1)
  • S2 troke / TIA / Thromboembolism (+2)
  • V ascular disease (prior MI, PAD, aortic plaque) (+1)
  • A ge 65–74 years (+1)
  • Sc ex category (Female) (+1)

Recommendation: Score ≥ 2 \ge 2 ≥ 2 in men or ≥ 3 \ge 3 ≥ 3 in women mandates oral anticoagulation with Direct Oral Anticoagulants (DOACs: Apixaban, Rivaroxaban, Dabigatran) preferred over Warfarin.

Rate Control vs Rhythm Control:

Rate Control: Target resting HR <110 bpm using Beta-blockers (Metoprolol), Non-dihydropyridine CCBs (Diltiazem, Verapamil - avoid CCBs in HFrEF! ), or Digoxin.

Rhythm Control: Electrical cardioversion or antiarrhythmic drugs (Amiodarone, Flecainide, Propafenone). If AF duration > 48 hours >48 \text{ hours} > 48 hours , anticoagulation for at least 3 weeks prior and 4 weeks after cardioversion is required (or TTE/TEE to exclude LA appendage thrombus).

Supraventricular Tachycardia (SVT / AVNRT)

ECG: Regular, narrow QRS complex (<120 ms), rate 150-250 bpm, P waves hidden or retrogradely buried in QRS.

Management Algorithm:

Hemodynamically Unstable → \rightarrow → Immediate Synchronized Cardioversion (50-100 J).

Hemodynamically Stable → \rightarrow → Vagal Maneuvers (modified Valsalva or carotid sinus massage).

Pharmacotherapy → \rightarrow → Adenosine 6 mg 6 \text{ mg} 6 mg rapid IV push followed by 20 mL 20 \text{ mL} 20 mL saline flush. If no conversion within 1-2 min, give 12 mg 12 \text{ mg} 12 mg rapid IV push . (Side effects: flushing, bronchospasm, transient cardiac arrest/asystole).

Second-line: IV Beta-blockers or IV Diltiazem/Verapamil.

Ventricular Tachycardia (VT) vs Wide-Complex Tachycardia

ECG: Broad QRS complex ( ≥ 120 ms \ge 120 \text{ ms} ≥ 120 ms ), rate >100 bpm. Assume ANY wide-complex tachycardia is VT until proven otherwise.

Brugada Criteria for VT: Absence of RS complex in all precordial leads, RS interval >100 ms, AV dissociation, fusion or capture beats.

Management:

Pulseless VT or VF: Immediate unsynchronized high-energy shock (Defibrillation 200J biphasic) + CPR.

Unstable VT with Pulse: Immediate Synchronized Cardioversion (100J).

Stable Monomorphic VT: IV Amiodarone ( 150 mg 150 \text{ mg} 150 mg over 10 min followed by infusion) or IV Procainamide .

Atrioventricular (AV) Heart Blocks

Type of AV Block ECG Characteristic Clinical Features & Management

First-Degree Prolonged PR interval ( > 200 ms >200 \text{ ms} > 200 ms ), constant, 1:1 AV conduction Usually benign, asymptomatic. No treatment required.

Second-Degree Mobitz I (Wenckebach) Progressive prolongation of PR interval until a QRS complex is dropped AV nodal block. Often transient/benign (vagal tone, inferior MI). Monitor.

Second-Degree Mobitz II Constant PR interval followed by intermittent sudden dropped QRS Infranodal block (His-Purkinje system). High risk of progression to complete heart block. Requires Permanent Pacemaker .

Third-Degree (Complete) Complete AV dissociation; P waves and QRS complexes occur independently Severe bradycardia, syncope (Stokes-Adams attacks). Emergency Transcutaneous/Transvenous Pacing followed by Permanent Pacemaker.

Loading diagram... Acute Tachycardia Management Algorithm